CITADEL 203 (#761)
Laufzeit: 01.01.2018 - 31.12.2019
imported
Kurzfassung
A phase 2, multicenter, open-label, randomized study comparing INCB050465, a PI3K inhibitor, to Idelalisib in relapsed or refractory follicular lymphoma (CITADEL-203)
